3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
86
Ovarian Neoplasms
33
Breast Neoplasms
29
Carcinoma, Non-Small-Cell Lung
28
Colonic Neoplasms
23
Rectal Neoplasms
21
Fallopian Tube Neoplasms
17
Neoplasms
16
Neoplasm Metastasis
13
Carcinoma, Hepatocellular
13
Glioblastoma
11
Lung Neoplasms
10
Brain Neoplasms
8
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Intestinal Neoplasms
5
Gastrointestinal Neoplasms
5
Digestive System Neoplasms
5
Brenner Tumor
5
Recurrence
4
Peritoneal Neoplasms
4
Glioma
4
Carcinoma, Ovarian Epithelial
4
Adenocarcinoma of Lung
4
Rectal Diseases
3
Non-Squamous Non-Small Cell Lung Cancer
3
Liver Neoplasms
3
Intestinal Diseases
3
Gastrointestinal Diseases
3
Interventions
padeliporfin
3
Mitomycin
2
valrubicin
1
temsirolimus
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
enfortumab vedotin
1
abiraterone
1
abemaciclib
1
Tadalafil
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Prednisone
1
Prednisolone
1
Phosphodiesterase 5 Inhibitors
1
Gemcitabine
1
Fluorouracil
1
Drug Therapy
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urogenital Neoplasms
×
Bevacizumab
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts